-+ 0.00%
-+ 0.00%
-+ 0.00%

Ernexa Q1 net loss narrows 32.87% to $5.51 million; no revenue

PUBT·05/11/2026 21:03:16
Listen to the news
Ernexa Q1 net loss narrows 32.87% to $5.51 million; no revenue
  • Ernexa Therapeutics posted a net loss of USD 5.51 million for the quarter ended March 31, 2026, narrowing from USD 8.2 million a year earlier.
  • Operating loss widened to USD 5.59 million from USD 2.73 million, driven by a USD 2.04 million goodwill impairment charge.
  • Research and development expense climbed to USD 1.92 million from USD 1.31 million on higher ERNA-101 study fees, while general and administrative costs rose to USD 1.63 million from USD 1.42 million.
  • Cash totaled about USD 9.2 million at March 31, 2026, and operating cash outflow was USD 2.26 million; net proceeds from a February public offering were about USD 9.5 million.
  • Company reiterated plans to complete IND-enabling work and submit an IND in 2026, targeting a Phase I investigator-sponsored trial of ERNA-101 in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022276), on May 11, 2026, and is solely responsible for the information contained therein.